184 related articles for article (PubMed ID: 36859649)
1. Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study.
Oswald AJ; Symeonides SN; Wheatley D; Chan S; Brunt AM; McAdam K; Schmid P; Waters S; Poole C; Twelves C; Perren T; Bartlett J; Piper T; Chisholm EM; Welsh M; Hill R; Hopcroft LEM; Barrett-Lee P; Cameron DA
Breast Cancer Res Treat; 2023 May; 199(1):35-46. PubMed ID: 36859649
[TBL] [Abstract][Full Text] [Related]
2. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.
Johnston SR; Kilburn LS; Ellis P; Dodwell D; Cameron D; Hayward L; Im YH; Braybrooke JP; Brunt AM; Cheung KL; Jyothirmayi R; Robinson A; Wardley AM; Wheatley D; Howell A; Coombes G; Sergenson N; Sin HJ; Folkerd E; Dowsett M; Bliss JM;
Lancet Oncol; 2013 Sep; 14(10):989-98. PubMed ID: 23902874
[TBL] [Abstract][Full Text] [Related]
3. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
4. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE.
Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ
J Clin Oncol; 2021 Jan; 39(1):79-89. PubMed ID: 32822287
[TBL] [Abstract][Full Text] [Related]
5. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Howell SJ; Casbard A; Carucci M; Ingarfield K; Butler R; Morgan S; Meissner M; Bale C; Bezecny P; Moon S; Twelves C; Venkitaraman R; Waters S; de Bruin EC; Schiavon G; Foxley A; Jones RH
Lancet Oncol; 2022 Jul; 23(7):851-864. PubMed ID: 35671774
[TBL] [Abstract][Full Text] [Related]
6. E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.
Connolly RM; Zhao F; Miller KD; Lee MJ; Piekarz RL; Smith KL; Brown-Glaberman UA; Winn JS; Faller BA; Onitilo AA; Burkard ME; Budd GT; Levine EG; Royce ME; Kaufman PA; Thomas A; Trepel JB; Wolff AC; Sparano JA
J Clin Oncol; 2021 Oct; 39(28):3171-3181. PubMed ID: 34357781
[TBL] [Abstract][Full Text] [Related]
7. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
[TBL] [Abstract][Full Text] [Related]
9. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Jones RH; Casbard A; Carucci M; Cox C; Butler R; Alchami F; Madden TA; Bale C; Bezecny P; Joffe J; Moon S; Twelves C; Venkitaraman R; Waters S; Foxley A; Howell SJ
Lancet Oncol; 2020 Mar; 21(3):345-357. PubMed ID: 32035020
[TBL] [Abstract][Full Text] [Related]
10. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
11. Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial.
Guarneri V; Giorgi CA; Cinieri S; Bengala C; Mariani G; Bisagni G; Frassoldati A; Zamagni C; De Rossi C; Amoroso V; Andreetta C; Ferro A; Zambelli A; Gori S; Garrone O; Dieci MV; Orlando L; Pastina I; Beninato T; Moretti G; Genovesi E; Cinefra M; Vicini R; Magni G; De Salvo GL; Conte P
Eur J Cancer; 2021 Sep; 154():21-29. PubMed ID: 34225066
[TBL] [Abstract][Full Text] [Related]
12. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
Krop IE; Mayer IA; Ganju V; Dickler M; Johnston S; Morales S; Yardley DA; Melichar B; Forero-Torres A; Lee SC; de Boer R; Petrakova K; Vallentin S; Perez EA; Piccart M; Ellis M; Winer E; Gendreau S; Derynck M; Lackner M; Levy G; Qiu J; He J; Schmid P
Lancet Oncol; 2016 Jun; 17(6):811-821. PubMed ID: 27155741
[TBL] [Abstract][Full Text] [Related]
13. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Jiang Z; Li W; Hu X; Zhang Q; Sun T; Cui S; Wang S; Ouyang Q; Yin Y; Geng C; Tong Z; Cheng Y; Pan Y; Sun Y; Wang H; Ouyang T; Gu K; Feng J; Wang X; Wang S; Liu T; Gao J; Cristofanilli M; Ning Z; Lu X
Lancet Oncol; 2019 Jun; 20(6):806-815. PubMed ID: 31036468
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson L; Lawrence D; Dawson C; Bliss J
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD003370. PubMed ID: 19821307
[TBL] [Abstract][Full Text] [Related]
15. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.
Kornblum N; Zhao F; Manola J; Klein P; Ramaswamy B; Brufsky A; Stella PJ; Burnette B; Telli M; Makower DF; Cheema P; Truica CI; Wolff AC; Soori GS; Haley B; Wassenaar TR; Goldstein LJ; Miller KD; Sparano JA
J Clin Oncol; 2018 Jun; 36(16):1556-1563. PubMed ID: 29664714
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer.
Gucalp A; Sparano JA; Caravelli J; Santamauro J; Patil S; Abbruzzi A; Pellegrino C; Bromberg J; Dang C; Theodoulou M; Massague J; Norton L; Hudis C; Traina TA
Clin Breast Cancer; 2011 Oct; 11(5):306-11. PubMed ID: 21729667
[TBL] [Abstract][Full Text] [Related]
17. Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.
Chen Y; Guggisberg N; Jorda M; Gonzalez-Angulo A; Hennessy B; Mills GB; Tan CK; Slingerland JM
Clin Cancer Res; 2009 May; 15(10):3396-405. PubMed ID: 19451593
[TBL] [Abstract][Full Text] [Related]
18. A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.
McNeish IA; Ledermann JA; Webber L; James L; Kaye SB; Hall M; Hall G; Clamp A; Earl H; Banerjee S; Kristeleit R; Raja F; Feeney A; Lawrence C; Dawson-Athey L; Persic M; Khan I
Ann Oncol; 2014 Oct; 25(10):1988-1995. PubMed ID: 25070546
[TBL] [Abstract][Full Text] [Related]
19. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.
Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ
J Clin Oncol; 2018 Mar; 36(8):741-748. PubMed ID: 29244528
[TBL] [Abstract][Full Text] [Related]
20. First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial.
Rimawi M; Ferrero JM; de la Haba-Rodriguez J; Poole C; De Placido S; Osborne CK; Hegg R; Easton V; Wohlfarth C; Arpino G;
J Clin Oncol; 2018 Oct; 36(28):2826-2835. PubMed ID: 30106636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]